Guest Editorial Optimize the dose: An optimal step forward for FDA June 11, 2021Vol.47 No.23By Mark J. Ratain, Garth W. Strohbehn, Ian F. Tannock and Allen S. Lichter
Conversation with The Cancer LetterFree We ask FDA to explain “dangling” accelerated approvals—and this week’s ODAC agenda April 30, 2021Vol.47 No.17By Paul Goldberg
Free FDA’s Critics Call for Full Integration of Oncology Center Under Biden’s Moonshot May 06, 2016Vol.42 No.18By Matthew Bin Han Ong
